UniProt P54764 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: aa 616-887high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Bosutinib | 99.6% | 0.4% | 87.22 | 0.555 |
| 2 | Ponatinib | 98.3% | 1.7% | 78.23 | 0.534 |
| 3 | Dasatinib | 98.3% | 1.7% | 87.97 | 0.699 |
| 4 | Repotrectinib | 95.6% | 4.4% | 84.21 | 0.608 |
| 5 | Cabozantinib | 94.5% | 5.5% | 92.73 | 0.751 |
| 6 | Nilotinib | 94.4% | 5.6% | 96.49 | 0.765 |
| 7 | Ripretinib | 93.1% | 6.9% | 92.95 | 0.674 |
| 8 | Fostamatinib | 91.5% | 8.5% | 96.74 | 0.613 |
| 9 | Crizotinib | 89.3% | 10.7% | 91.39 | 0.581 |
| 10 | Tivozanib | 83.7% | 16.3% | 92.42 | 0.673 |
| 11 | Vandetanib | 82.1% | 17.9% | 95.74 | 0.723 |
| 12 | Erdafitinib | 81.5% | 18.5% | 95.71 | 0.737 |
| 13 | Canertinib | 63.2% | 36.8% | 96.49 | 0.671 |
| 14 | Afatinib | 47.6% | 52.4% | 98.50 | 0.709 |
| 15 | Apatinib | 45.4% | 54.6% | 97.73 | 0.704 |
| 16 | Regorafenib | 40.9% | 59.1% | 95.99 | 0.719 |
| 17 | Selpercatinib | 37.7% | 62.3% | 96.72 | 0.635 |
| 18 | Dacomitinib | 37.7% | 62.3% | 97.99 | 0.664 |
| 19 | Gefitinib | 37.1% | 62.9% | 99.25 | 0.650 |
| 20 | Nintedanib | 34.8% | 65.2% | 90.23 | 0.608 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 2.48
- Epithelial log2(TPM+1): 1.37
- Fold change: 1.10
- Status: Upregulated
High-confidence drugs
- Nilotinib — inh 94.4% · KISS 44.94
- Dasatinib — inh 98.3% · KISS 40.41
- Cabozantinib — inh 94.5% · KISS 39.50
Selectivity landscape vs inhibition on EPHA4
Each point is one of the 92 approved drugs; color = inhibition % on EPHA4.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…